Replies to post #204029 on Anavex Life Sciences Corp (AVXL)

[Cbdpotential]

Unnecessary perhaps for those familiar with Anavex but this news release could have been negative instead of positive/neutral
I don’t believe this is any sort of fluff
Simply keeping shareholders informed on new 3rd party findings/recommendations
To brand new eyes this is good news in my opinion
It’s interesting to see minimal reaction (seems the market has a bit more confidence in AVXL than it may seem)
All Jmho

[Steady_T]

Today's news is nice but it seems a bit unnecessary because everyone knew Anavex was safe from the P2A trials.

If everyone knew 2-73 was safe then the FDA wouldn't have wanted the safety trial in the first place.

What we know is that 2-73 had very mild toxicity issues in the elderly population diagnosed with AD.

The much younger population of girls with Rett syndrome have a whole host of issues related to the brain chemistry problems caused by the mutated gene. These girls have developmental issues that AD subjects do not just to mention one big difference.

The safety trial is needed on the older Rett patients to establish a probability that 2-73 will not cause obvious problems for the younger, still developing Rett girls that could be vulnerable to things that mature individuals would not be subject to.

The young girls still have developing brains and bodies that offer many more opportunities for things to go wrong.